Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase.

A series of alpha-ketooxazoles containing conformational constraints in the flexible C2 acyl side chain of 2 (OL-135) and representative oxazole C5 substituents were prepared and examined as inhibitors of fatty acid amide hydrolase (FAAH). Exceptionally potent and selective FAAH inhibitors emerged from the series (e.g., 6, Ki = 200 and 260 pM for rat and rhFAAH). With simple and small C5 oxazole substituents, each series bearing a biphenylethyl, phenoxyphenethyl, or (phenoxymethyl)phenethyl C2 side chain was found to follow a well-defined linear relationship between -log Ki and Hammett sigmap of a magnitude (rho = 2.7-3.0) that indicates that the substituent electronic effect dominates, confirming its fundamental importance to the series and further establishing its predictive value. Just as significantly, the nature of the C5 oxazole substituent substantially impacts the selectivity of the inhibitors whereas the effect of the C2 acyl chain was more subtle but still significant even in the small series examined. Combination of these independent features, which display generalized trends across a range of inhibitor series, simultaneously improves FAAH potency and selectivity and can provide exquisitely selective and potent FAAH inhibitors.

[1]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Heterocyclic sulfoxide and sulfone inhibitors of fatty acid amide hydrolase. , 2005, Bioorganic & medicinal chemistry letters.

[3]  B. Cravatt,et al.  Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. , 2001, Vitamins and hormones.

[4]  E. Vedejs,et al.  Metalation of Oxazole−Borane Complexes: A Practical Solution to the Problem of Electrocyclic Ring Opening of 2-Lithiooxazoles , 1996 .

[5]  W. A. Hill,et al.  Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. , 1997, Biochemical and biophysical research communications.

[6]  R. Lerner,et al.  Chemical characterization of a family of brain lipids that induce sleep. , 1995, Science.

[7]  D. Boger,et al.  Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition. , 1999, Bioorganic & medicinal chemistry letters.

[8]  D. Boger,et al.  Delineation of a fundamental alpha-ketoheterocycle substituent effect for use in the design of enzyme inhibitors. , 2006, Journal of the American Chemical Society.

[9]  C. Fowler,et al.  The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. , 2005, Journal of medicinal chemistry.

[10]  J. Brioni,et al.  Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets , 2007, Neuropharmacology.

[11]  L. Petrocellis,et al.  Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. , 1997, Biochemical and biophysical research communications.

[12]  Qing‐Yun Chen,et al.  Methyl fluorosulphonyldifluoroacetate; a new trifluoromethylating agent , 1989 .

[13]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[14]  D. Boger,et al.  Structure−Activity Relationships of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase , 2007 .

[15]  B. Cravatt,et al.  Molecular characterization of human and mouse fatty acid amide hydrolases. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Cristiano Ruch Werneck Guimarães,et al.  Elucidation of fatty acid amide hydrolase inhibition by potent alpha-ketoheterocycle derivatives from Monte Carlo simulations. , 2005, Journal of the American Chemical Society.

[17]  Vittorio Farina,et al.  The Stille reaction , 1997 .

[18]  S. Werner,et al.  Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System , 2007, Science.

[19]  R. Mechoulam,et al.  Discovery and characterization of endogenous cannabinoids. , 1999, Life sciences.

[20]  Alan Saghatelian,et al.  Functional disassociation of the central and peripheral fatty acid amide signaling systems. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Deutsch,et al.  Inhibitors of arachidonoyl ethanolamide hydrolysis. , 1994, The Journal of biological chemistry.

[22]  M. Elphick,et al.  Comparative analysis of fatty acid amide hydrolase and cb1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling , 2003, Neuroscience.

[23]  A. Duranti,et al.  Synthesis and Structure–Activity Relationships of FAAH Inhibitors: Cyclohexylcarbamic Acid Biphenyl Esters with Chemical Modulation at the Proximal Phenyl Ring , 2006, ChemMedChem.

[24]  B. Cravatt,et al.  Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. , 1999, Biochemistry.

[25]  B. Cravatt,et al.  The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. , 2006, Journal of the American Chemical Society.

[26]  Raymond C Stevens,et al.  Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.

[27]  B. Cravatt,et al.  Increased Seizure Susceptibility and Proconvulsant Activity of Anandamide in Mice Lacking Fatty Acid Amide Hydrolase , 2003, The Journal of Neuroscience.

[28]  W. Campbell,et al.  Synthesis and characterization of diazomethylarachidonyl ketone: an irreversible inhibitor of N-arachidonylethanolamine amidohydrolase. , 1998, The Journal of pharmacology and experimental therapeutics.

[29]  B. Cravatt,et al.  Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. , 2003, Current opinion in chemical biology.

[30]  R. Lerner,et al.  Structure Determination of an Endogenous Sleep-Inducing Lipid, cis-9-Octadecenamide (Oleamide): A Synthetic Approach to the Chemical Analysis of Trace Quantities of a Natural Product , 1996 .

[31]  B. Cravatt,et al.  Profiling serine hydrolase activities in complex proteomes. , 2001, Biochemistry.

[32]  G. Nomikos,et al.  Identification of a high-affinity binding site involved in the transport of endocannabinoids. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Schmid,et al.  N-acylated glycerophospholipids and their derivatives. , 1990, Progress in lipid research.

[34]  A. Saghatelian,et al.  Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity , 2004, Journal of Pharmacology and Experimental Therapeutics.

[35]  Benjamin F. Cravatt,et al.  Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase , 2007 .

[36]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[37]  Giovanni Piersanti,et al.  Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. , 2004, Journal of medicinal chemistry.

[38]  D. Dess,et al.  A useful 12-I-5 triacetoxyperiodinane (the Dess-Martin periodinane) for the selective oxidation of primary or secondary alcohols and a variety of related 12-I-5 species , 1991 .

[39]  D. Boger,et al.  Fatty acid amide hydrolase substrate specificity. , 2000, Bioorganic & medicinal chemistry letters.

[40]  Y. Yamagata,et al.  Effective synthesis of C-nucleosides with 2′,4′-BNA modification , 2002 .

[41]  S. Henriksen,et al.  Effect of Oleamide on Sleep and Its Relationship to Blood Pressure, Body Temperature, and Locomotor Activity in Rats , 2001, Experimental Neurology.

[42]  D. Boger,et al.  An endogenous sleep-inducing compound is a novel competitive inhibitor of fatty acid amide hydrolase. , 1998, Bioorganic & medicinal chemistry letters.

[43]  B. Cravatt,et al.  Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia , 2004, Pain.

[44]  D. Boger,et al.  Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity. , 2005, Bioorganic & medicinal chemistry letters.

[45]  B. Cravatt,et al.  Clarifying the Catalytic Roles of Conserved Residues in the Amidase Signature Family* , 2000, The Journal of Biological Chemistry.

[46]  D. Deutsch,et al.  Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. , 1997, Biochemical pharmacology.

[47]  B. Cravatt,et al.  Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties. , 1999, Biochemistry.

[48]  A. Saghatelian,et al.  An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. , 2006, Chemistry & biology.

[49]  K. Abouzid,et al.  Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. , 1999, Journal of medicinal chemistry.

[50]  Sandy J. Wilson,et al.  Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms , 2006 .

[51]  L. Petrocellis,et al.  Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. , 1999, Current medicinal chemistry.

[52]  B. Cravatt,et al.  Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. , 2005, Chemistry & biology.

[53]  G. Scriba,et al.  Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates. , 2006, Journal of medicinal chemistry.

[54]  Daniele Piomelli,et al.  Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models , 2006, British journal of pharmacology.

[55]  I. Ollmann,et al.  Inhibition of Oleamide Hydrolase Catalyzed Hydrolysis of the Endogenous Sleep-Inducing Lipid cis-9-Octadecenamide , 1996 .

[56]  B. Cravatt,et al.  Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. , 1998, Biochemistry.

[57]  D. Boger,et al.  α-Keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and α-substitution , 2001 .

[58]  S. Henriksen,et al.  Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. , 1998, Current pharmaceutical design.

[59]  Dale L Boger,et al.  Discovering potent and selective reversible inhibitors of enzymes in complex proteomes , 2003, Nature Biotechnology.

[60]  Antti Poso,et al.  Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. , 2006, Journal of medicinal chemistry.

[61]  C. Fowler,et al.  Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. , 2001, Biochemical pharmacology.

[62]  A. Duranti,et al.  Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. , 2003, Journal of medicinal chemistry.

[63]  D. Boger,et al.  Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Pertwee,et al.  Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist , 1997, British journal of pharmacology.

[65]  Marya Liimatta,et al.  Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. , 2007, Biochemistry.